ResMed (RMD) Projected to Release Earnings on Thursday

ResMed (NYSE:RMD - Get Free Report) is projected to announce its Q1 2027 results after the market closes on Thursday, October 29th. Analysts expect ResMed to post earnings of $2.69 per share and revenue of $1.39 billion for the quarter. Interested persons can find conference call details on the company's upcoming Q1 2027 earnings report page for the latest details on the call scheduled for Thursday, October 29, 2026 at 4:30 PM ET.

ResMed (NYSE:RMD - Get Free Report) last posted its quarterly earnings data on Thursday, August 6th. The medical equipment provider reported $2.95 earnings per share for the quarter, topping the consensus estimate of $2.89 by $0.06. ResMed had a net margin of 26.94% and a return on equity of 25.58%. The firm had revenue of $1.46 billion during the quarter, compared to analysts' expectations of $1.46 billion. During the same quarter in the previous year, the company posted $2.55 EPS. ResMed's revenue was up 8.6% on a year-over-year basis. On average, analysts expect ResMed to post $12.06 EPS for the current fiscal year and $13.08 EPS for the next fiscal year.

ResMed Stock Up 0.4%

NYSE:RMD opened at $246.45 on Thursday. The company has a market cap of $34.66 billion, a price-to-earnings ratio of 23.63, a P/E/G ratio of 1.51 and a beta of 0.75. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.42 and a current ratio of 3.10. The stock's fifty day moving average price is $228.61 and its two-hundred day moving average price is $214.79. ResMed has a 52-week low of $180.26 and a 52-week high of $277.67.

ResMed Increases Dividend

The company also recently declared a quarterly dividend, which was paid on Thursday, September 24th. Stockholders of record on Thursday, August 20th were paid a dividend of $0.66 per share. This represents a $2.64 annualized dividend and a dividend yield of 1.1%. This is a boost from ResMed's previous quarterly dividend of $0.60. The ex-dividend date of this dividend was Thursday, August 20th. ResMed's payout ratio is currently 25.31%.

Wall Street Analysts Forecast Growth

RMD has been the subject of a number of research reports. Piper Sandler lowered their price objective on ResMed from $233.00 to $225.00 and set a "neutral" rating for the company in a research report on Friday, August 7th. The Goldman Sachs Group reissued a "buy" rating on shares of ResMed in a report on Wednesday, July 1st. Citigroup restated a "neutral" rating on shares of ResMed in a research report on Thursday, September 10th. Royal Bank Of Canada raised shares of ResMed from a "sector perform" rating to an "outperform" rating and raised their target price for the company from $244.00 to $262.00 in a research note on Tuesday, September 15th. Finally, UBS Group reiterated a "buy" rating and set a $300.00 price target on shares of ResMed in a research report on Tuesday, July 21st. Seven investment analysts have rated the stock with a Buy rating and nine have given a Hold rating to the company's stock. According to MarketBeat.com, the stock has a consensus rating of "Hold" and a consensus target price of $243.23.

Insiders Place Their Bets

In related news, Director Peter Farrell sold 970 shares of ResMed stock in a transaction on Wednesday, September 2nd. The stock was sold at an average price of $234.73, for a total transaction of $227,688.10. Following the completion of the sale, the director directly owned 51,803 shares of the company's stock, valued at $12,159,718.19. The trade was a 1.84% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Michael Farrell sold 4,991 shares of the company's stock in a transaction dated Wednesday, October 7th. The shares were sold at an average price of $226.33, for a total value of $1,129,613.03. Following the completion of the sale, the chief executive officer owned 479,803 shares of the company's stock, valued at $108,593,812.99. This represents a 1.03% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders have sold 23,943 shares of company stock valued at $5,294,098. 0.58% of the stock is owned by insiders.

ResMed Company Profile

ResMed Inc is a medical equipment and software company that develops solutions for sleep-disordered breathing, respiratory conditions and other chronic diseases. The company is best known for its positive airway pressure (PAP) devices used to treat obstructive sleep apnea, along with masks, accessories and related patient support services.

ResMed also provides cloud-connected health technology, including remote-monitoring platforms and software used by healthcare providers, medical equipment suppliers and care organizations.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.